Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
PLoS One ; 18(10): e0292527, 2023.
Article in English | MEDLINE | ID: mdl-37797059

ABSTRACT

Alzheimer's disease (AD) is a highly heterogeneous disorder. Untangling this variability could lead to personalized treatments and improve participant recruitment for clinical trials. We investigated the cognitive subgroups by using a data-driven clustering technique in an AD cohort. People with mild-moderate probable AD from Taiwan was included. Neuropsychological test results from the Cognitive Abilities Screening Instrument were clustered using nonnegative matrix factorization. We identified two clusters in 112 patients with predominant deficits in memory (62.5%) and non-memory (37.5%) cognitive domains, respectively. The memory group performed worse in short-term memory and orientation and better in attention than the non-memory group. At baseline, patients in the memory group had worse global cognitive status and dementia severity. Linear mixed effect model did not reveal difference in disease trajectory within 3 years of follow-up between the two clusters. Our results provide insights into the cognitive heterogeneity in probable AD in an Asian population.


Subject(s)
Alzheimer Disease , Cognition Disorders , Humans , Alzheimer Disease/epidemiology , Cognition Disorders/psychology , Neuropsychological Tests , Taiwan
2.
Taiwan J Obstet Gynecol ; 62(2): 330-333, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36965903

ABSTRACT

OBJECTIVE: What is the more efficient and safer protocol during controlled ovarian hyperstimulation (COH) for early-stage breast cancer patients seeking emergency fertility preservation before adjuvant chemo/radiotherapy? MATERIALS AND METHODS: This retrospective, case-series study involved two early-stage (Ia) breast cancer patients that requested for fertility preservation within 3 weeks. Random start/dual stimulation protocols with aromatase inhibitor (AI) were used to maximize oocyte yield and suppress serum estradiol (E2) level. RESULTS: E2 levels on trigger day during dual COH were between 112.0 and 407.0 pg/mL. Duration of COH could be shortened to only 17 days, and up to 41 oocytes were successfully retrieved with two retrievals. CONCLUSION: This remarkable efficient and safe protocol involves the combination of random start/dual stimulation with step-up AI dosage beforehand which not only maximize oocyte yield within the shortest possible timeframe, but also to maintain the low level of E2 to avoid over-stimulating estrogen-sensitive cancer cells and to decrease the risk of developing ovarian hyperstimulation syndrome (OHSS).


Subject(s)
Breast Neoplasms , Fertility Preservation , Ovarian Hyperstimulation Syndrome , Female , Humans , Fertility Preservation/methods , Retrospective Studies , Aromatase Inhibitors/adverse effects , Estrogens , Ovulation Induction/methods , Ovarian Hyperstimulation Syndrome/prevention & control , Breast Neoplasms/therapy , Oocytes/physiology
3.
J Chin Med Assoc ; 84(11): 1048-1053, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34747901

ABSTRACT

BACKGROUND: Ovarian clear cell carcinoma (OCCC) is frequently associated with endometriosis. Since serum levels of cancer antigen 125 (CA125) have limited diagnostic and prognostic value in this malignancy, there is an unmet need for reliable and specific biomarkers. Previous findings indicated that alpha 1-antitrypsin isoforms (isoAAT) are significantly increased in the peritoneal fluid of patients with endometriosis. This study was undertaken to examine whether serum isoAAT levels in patients with OCCC differ from those measured in women with endometriosis or benign ovarian tumors. We also investigated whether this biomarker may be useful for predicting survival in OCCC. METHODS: Paired serum samples before and after debulking surgery were collected from 27 patients with OCCC. All sera from patients with endometriosis (n = 44) and benign ovarian tumors (n = 32) were obtained in the pretreatment phase. Serum isoAAT levels were assayed using a proprietary ELISA kit. RESULTS: The highest levels of serum isoAAT (median, range) were identified in patients with OCCC (preoperative values: 160.9 ng/mL, range, 101.4-1098.8 ng/mL), followed by patients with endometriosis (125.0 and 83.4-473.2 ng/mL), and those with benign tumors (125.2 and 60.5-191.3 ng/mL). The differences in serum isoAAT levels between patients with OCCC and benign tumors were significant (p = 0.041). Debulking surgery of OCCC resulted in a significant decrease in serum isoAAT levels compared with the preoperative period (median, 160.9 versus 113.0 ng/mL, respectively, p = 0.012). As for prognostic prediction, we found that none of the nine patients with OCCC and serum isoAAT levels ≤130 ng/mL died of disease. CONCLUSION: Serum isoAAT levels may be diagnostically useful to distinguish OCCC from benign ovarian tumors and could also serve as a potential prognostic marker.


Subject(s)
Adenocarcinoma, Clear Cell , Ovarian Neoplasms , Protein Isoforms/blood , alpha 1-Antitrypsin/blood , Biomarkers, Tumor , Endometriosis/physiopathology , Female , Humans , Ovarian Neoplasms/physiopathology , Retrospective Studies
4.
PLoS One ; 15(4): e0231594, 2020.
Article in English | MEDLINE | ID: mdl-32315343

ABSTRACT

Recurrence and poorly differentiated (grade 3 and above) and atypical cell type endometrial cancer (EC) have poor prognosis outcome. The mechanisms and characteristics of recurrence and distal metastasis of EC remain unclear. The extracellular matrix (ECM) of the reproductive tract in women undergoes extensive structural remodelling changes every month. Altered ECMs surrounding cells were believed to play crucial roles in a cancer progression. To decipher the associations between ECM and EC development, we generated a PAN-ECM Data list of 1516 genes including ECM molecules (ECMs), synthetic and degradation enzymes for ECMs, ECM receptors, and soluble molecules that regulate ECM and used RNA-Seq data from The Cancer Genome Atlas (TCGA) for the studies. The alterations of PAN-ECM genes by comparing the RNA-Seq expressions profiles of EC samples which have been grouped as tumorigenesis and metastasis group based on their pathological grading were identified. Differential analyses including functional enrichment, co-expression network, and molecular network analysis were carried out to identify the specific PAN-ECM genes that may involve in the progression of EC. Eight hundred and thirty-one and 241 PAN-ECM genes were significantly involved in tumorigenesis (p-value <1.571e-15) and metastasis (p-value <2.2e-16), respectively, whereas 140 genes were in the intersection of tumorigenesis and metastasis. Interestingly, 92 of the 140 intersecting PAN-ECM genes showed contrasting fold changes between the tumorigenesis and metastasis datasets. Enrichment analysis for the contrast PAN-ECM genes indicated pathways such as GP6 signaling, ILK signaling, and interleukin (IL)-8 signaling pathways were activated in metastasis but inhibited in tumorigenesis. The significantly activated ECM and ECM associated genes in GP6 signaling, ILK signaling, and interleukin (IL)-8 signaling pathways may play crucial roles in metastasis of EC. Our study provides a better understanding of the etiology and the progression of EC.


Subject(s)
Carcinogenesis/genetics , Endometrial Neoplasms/genetics , Extracellular Matrix/genetics , Neoplasm Proteins/genetics , Computational Biology , Disease Progression , Endometrial Neoplasms/pathology , Endometrium/metabolism , Endometrium/pathology , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Neoplasm Metastasis , RNA-Seq , Receptors, Cell Surface/genetics , Signal Transduction/genetics
5.
Int J Mol Sci ; 20(18)2019 Sep 05.
Article in English | MEDLINE | ID: mdl-31491902

ABSTRACT

This study aimed to investigate the effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on the expression of neuritin 1 (NRN1) in women with ovarian endometriosis. We collected tissues and serum from women with endometriosis treated with (n = 45) or without (n = 37) GnRHa. NRN1 mRNA and protein levels were measured using qPCR and Western blot. Immunolocalization of NRN1 in endometriotic tissues was examined using immunohistochemistry. In addition, a follow-up study was carried out to monitor the serum level of NRN1 in patients before and after GnRHa treatment. Both mRNA (p = 0.046) and protein (p = 0.0155) levels of NRN1 were significantly lower in endometriotic tissues from patients receiving GnRHa treatment compared to the untreated group. Both epithelial and stromal cells of endometriotic tissues from untreated women with endometriosis exhibited stronger staining of NRN1 but not in those who were treated with GnRHa. The follow-up study showed that the serum level of the NRN1 concentration decreased significantly from 1149 ± 192.3 to 379.2 ± 80.16 pg/mL after GnRHa treatment (p = 0.0098). The expression of NRN1 was significantly lower in women with ovarian endometriosis treated with GnRHa. These results suggest that NRN1 may be a biomarker response to the effect of GnRHa treatment for patients with ovarian endometriosis.


Subject(s)
Endometriosis/etiology , Endometriosis/metabolism , Gonadotropin-Releasing Hormone/agonists , Neuropeptides/genetics , Ovary/pathology , Adult , Biomarkers , Biopsy , Endometriosis/drug therapy , Endometriosis/pathology , Female , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Gene Expression , Gene Expression Regulation/drug effects , Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/pharmacology , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Middle Aged , Neuropeptides/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Young Adult
6.
Int J Nanomedicine ; 13: 7251-7273, 2018.
Article in English | MEDLINE | ID: mdl-30510416

ABSTRACT

INTRODUCTION: Dry-eye syndrome (DES) is a general eye disease. Eye drops are the common ophthalmological medication. However, the ocular barrier makes it difficult to attain high drug bioavailability. Nanomedicine is a promising alternative treatment for ocular diseases and may increase drug content in the affected eye. METHODS: To explore this potential, we constructed nanoparticles (NPs) containing an anti-inflammatory agent for DES treatment. The NPs were made of gelatin-epigallocatechin gallate (EGCG) with surface decoration by hyaluronic acid (HA) and designated "GEH". The particle size, surface charge, and morphology were evaluated. The in vitro biocompatibility and anti-inflammation effect of nanoparticles were assayed via culturing with human corneal epithelium cells (HCECs) and in vivo therapeutic effect was examined in a DES rabbit's model. RESULTS: The synthesized GEH NPs had a diameter of approximately 250 nm and were positively charged. A coculture experiment revealed that 20 µg/mL GEH was not cytotoxic to HCECs and that an EGCG concentration of 0.2 µg/mL downregulated the gene expression of IL1B and IL6 in inflamed HCECs. Large amounts of GEH NPs accumulated in the cytoplasm of HCECs and the ocular surfaces of rats and rabbits, indicating the advantage of GEH NPs for ocular delivery of medication. Twice-daily topical treatment with GEH NPs was performed in a rabbit model of DES. The ocular surface of GEH-treated rabbits displayed normal corneal architecture with no notable changes in inflammatory cytokine levels in the cornea lysate. The treatment improved associated clinical signs, such as tear secretion, and fluorescein staining recovered. CONCLUSION: We successfully produced GEH NPs with high affinity for HCECs and animal eyes. The treatment can be delivered as eye drops, which retain the drug on the ocular surface for a longer time. Ocular inflammation was effectively inhibited in DES rabbits. Therefore, GEH NPs are potentially valuable as a new therapeutic agent delivered in eye drops for treating DES.


Subject(s)
Catechin/analogs & derivatives , Dry Eye Syndromes/drug therapy , Gelatin/chemistry , Hyaluronic Acid/chemistry , Inflammation/drug therapy , Nanoparticles/chemistry , Ophthalmic Solutions/therapeutic use , Animals , Catechin/pharmacology , Catechin/therapeutic use , Cell Survival/drug effects , Cytokines/metabolism , Disease Models, Animal , Dry Eye Syndromes/pathology , Epithelial Cells/drug effects , Epithelium, Corneal/pathology , Humans , Male , Nanoparticles/ultrastructure , Ophthalmic Solutions/pharmacology , Particle Size , Rabbits , Rats , Sus scrofa , Tears , Treatment Outcome
7.
Crit Rev Oncol Hematol ; 108: 146-153, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27931833

ABSTRACT

Hyperglycemia is the most prominent sign that characterizes diabetes. Hyperglycemia favors malignant cell growth by providing energy to cancer cells. Clinical studies also showed an increased risk of diabetes being associated with different types of cancers. In addition, poorly regulated glucose metabolism in diabetic patients is often found with increased levels of chronic inflammatory markers, e.g., interleukin (IL)-1ß, IL-6, and tumor necrosis factor (TNF)-α, and emerging evidence has highlighted activation of the immune response in the progression and development of cancer cells. Therefore, uncontrolled proinflammatory responses could conceivably create a chronic inflammatory state, promoting a tumor-favorable microenvironment and potentially triggering immune overactivation and cancer growth. To further understand how hyperglycemia contributes to immune overactivation, the tumor microenvironment and the development of chronic inflammation-associated tumors may provide insights into tumor biology and immunology. This paper provides a brief introduction to hyperglycemia-associated diseases, followed by a comprehensive overview of the current findings of regulatory molecular mechanisms of glycosylation on proteoglycans in the extracellular matrix under hyperglycemic conditions. Then, the authors discuss the role of hyperglycemia in tumorigenesis (particularly in prostate, liver, colorectal, and pancreatic cancers), as well as the contribution of hyperglycemia to chronic inflammation. The authors end with a brief discussion on the future perspectives of hyperglycemia/tumorigenesis and potential applications of alternative/effective therapeutic strategies for hyperglycemia-associated cancers.


Subject(s)
Hyperglycemia , Inflammation , Neoplasms , Animals , Cell Transformation, Neoplastic , Chronic Disease , Diabetes Complications/epidemiology , Diabetes Mellitus , Humans , Hyperglycemia/epidemiology , Hyperglycemia/etiology , Inflammation/complications , Obesity/complications
8.
J Agric Food Chem ; 60(28): 7031-9, 2012 Jul 18.
Article in English | MEDLINE | ID: mdl-22708678

ABSTRACT

Sulforaphane (SFN) has been indicated for the prevention and suppression of tumorigenesis in solid tumors. Herein, we evaluated SFN's effects on imatinib (IM)-resistant leukemia stem cells (LSCs). CD34(+)/CD38(-) and CD34(+)/CD38(+) LSCs were isolated from KU812 cell line flowcytometrically. Isolated LSCs showed high expression of Oct4, CD133, ß-catenin, and Sox2 and IM resistance. Differentially, CD34(+)/CD38(-) LSCs demonstrated higher BCR-ABL and ß-catenin expression and imatinib (IM) resistance than CD34(+)/CD38(+) counterparts. IM and SFN combined treatment sensitized CD34(+)/CD38(-) LSCs and induced apoptosis, shown by increased caspase 3, PARP, and Bax while decreased Bcl-2 expression. Additionally, the combined treatment reduced BCR-ABL and ß-catenin and MDR-1 protein expression. Mechanistically, IM and SFN combined treatment resensitized LSCs by inducing intracellular reactive oxygen species (ROS). Importantly, ß-catenin-silenced LSCs exhibited reduced glutathione S-transferase pi 1 (GSTP1) expression and intracellular GSH level, which led to increased sensitivity toward IM and SFN. We demonstrated that IM and SFN combined treatment effectively eliminated CD34(+)/CD38(-) LSCs. Since SFN has been shown well tolerated in both animals and human, this regimen could be considered for clinical trials.


Subject(s)
Antineoplastic Agents/pharmacology , Leukemia/pathology , Piperazines/pharmacology , Pyrimidines/pharmacology , Thiocyanates/pharmacology , Wnt Signaling Pathway/drug effects , Wnt Signaling Pathway/physiology , ADP-ribosyl Cyclase 1/analysis , Anticarcinogenic Agents/pharmacology , Antigens, CD34/analysis , Apoptosis/drug effects , Benzamides , Cell Line, Tumor , Drug Resistance, Neoplasm , Drug Synergism , Gene Expression Regulation/drug effects , Glutathione/analysis , Glutathione S-Transferase pi/genetics , Humans , Imatinib Mesylate , Isothiocyanates , Leukemia/drug therapy , Leukemia/immunology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Neoplastic Stem Cells/chemistry , Neoplastic Stem Cells/drug effects , Sulfoxides , beta Catenin/antagonists & inhibitors
9.
Cells Tissues Organs ; 196(1): 23-33, 2012.
Article in English | MEDLINE | ID: mdl-22285908

ABSTRACT

Magnetic cryopreservation has been successfully used for tooth banking with satisfactory implantation outcomes, suggesting that the method preserves human periodontal ligament cells and dental pulp stem cells (DPSCs). Therefore, magnetic cryopreservation may be applied for the preservation of DPSCs; however, this method has not been evaluated yet. A reliable cryopreservation method for live-cell preservation is important for the clinical applications of regenerative medicine. The conventional slow-freezing procedure with 10% dimethylsulfoxide (DMSO) may not be appropriate for stem cell-based therapies because DMSO is cytotoxic. The objective of this study was to investigate whether magnetic cryopreservation can be applied for DPSC cryopreservation. Cells isolated from human dental pulp were subjected to magnetic cryopreservation. Postthawing cell viability, adhesion, proliferation, expression of markers for mesenchymal stem cells (MSCs), differentiation ability of magnetically cryopreserved DPSCs and DNA stability were compared to those of cells subjected to the conventional slow-freezing method. The results indicated that a serum-free cryopreservation medium (SFM) containing 3% DMSO is optimal for magnetic cryopreservation. Post-thaw magnetically cryopreserved DPSCs express MSC markers, and perform osteogenesis and adipogenesis after induction similarly to fresh MSCs. No significant DNA damage was found in magnetically cryopreserved DPSCs. Magnetic cryopreservation is thus a reliable and effective method for storage of DPSCs. The smaller amount of DMSO required in SFM for cryopreservation is beneficial for the clinical applications of post-thaw cells in regenerative medicine.


Subject(s)
Cryopreservation/methods , Cryoprotective Agents/pharmacology , Dental Pulp/cytology , Magnetics/methods , Stem Cells/cytology , Adult , Apoptosis/drug effects , Biomarkers/metabolism , Cell Adhesion/drug effects , Cell Differentiation/drug effects , Cell Proliferation/drug effects , DNA/metabolism , DNA Damage , Dimethyl Sulfoxide/pharmacology , Female , Freezing , Humans , Male , Stem Cells/drug effects , Stem Cells/metabolism
10.
Tissue Eng Part C Methods ; 18(6): 397-407, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22136083

ABSTRACT

Dental pulp, covered with dental hard tissue, is a promising source of mesenchymal stem cells and osteoprogenitor cells for regenerative medicine. Our previous studies showed that 73% of dental pulp cells isolated from magnetically cryopreserved teeth where their viability, morphology, and expression of stem cell surface markers were similar to the cells isolated from fresh teeth, suggesting that magnetic cryopreservation is an applicable method for intact tooth as well as dental pulp tissue banking. However, the cryoprotectant, concentration, contact surface, and equilibration time for magnetic cryopreservation of dental pulp require optimization. In addition, the integrity and viability of post-thawed dental pulp with and without dental hard tissue covering after magnetic cryopreservation were investigated. Lower concentration of the cryoprotectant (5% dimethyl sulfoxide [DMSO]) and shorter preequilibration time are required for magnetic cryopreservation compared with the conventional cryopreservation method. The structure of at least 33% of post-thawed pulp with dental hard tissue from the open end remained intact where >80% of cells were viable. The addition of the cryoprotectant additive trehalose did not replace or improve DMSO's efficacy for magnetic cryopreservation of dental pulp or intact tooth. Tooth banking for transplantation provides an alternative treatment to replace missing teeth. The optimized cryoprotectant conditions for dental pulp tissue during magnetic cryopreservation should lead to more satisfactory outcomes in clinical applications such as autotransplantation and the isolation and expansion of dental pulp stem cells for tissue repair.


Subject(s)
Cryopreservation/methods , Cryoprotective Agents/pharmacology , Dental Pulp/drug effects , Magnetics/methods , Animals , Cell Adhesion/drug effects , Cell Shape/drug effects , Dental Pulp/cytology , Freezing , Incisor/cytology , Incisor/drug effects , Male , Rats , Rats, Wistar , Tissue Survival/drug effects , Trehalose/pharmacology
11.
Oral Oncol ; 46(4): 226-31, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20138569

ABSTRACT

Sensitive and reliable early diagnostic markers for oral squamous cell carcinoma (OSCC) remain unavailable. Early identification of recurrence for OSCC is also a challenge. Unlike the other deep cancers, OSCC is located in oral cavity. The DNA, RNA, and protein derived from the living cancer cells and inflammatory cells then can be conveniently obtained from saliva. High-throughput genomic and proteomic approaches have been carried out to identify the potential biomarkers in body fluids such as saliva and blood for diagnosis and prognosis of OSCC. This article reviewed the recently identified biomarkers from saliva for OSCC. In addition, the biomarkers which have been correlated with OSCC tumor malignancy by molecular pathology analysis are also described. Finally, the potential biomarkers that have been demonstrated to associate with the malignant OSCC may be used for salivary screening for high-risk patients are suggested. This article may help to identify the potential biomarkers for screening and the molecular pathology analysis for high-risk patients of OSCC. Effective screening to identify high-risk patients can allow the clinician to provide the appropriate treatment without delay and to reduce the recurrence of OSCC.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/chemistry , Mouth Neoplasms/chemistry , Neoplasm Recurrence, Local/chemistry , Saliva/chemistry , Carcinoma, Squamous Cell/pathology , Female , Genomics , Humans , Male , Mouth Neoplasms/pathology , Neoplasm Recurrence, Local/prevention & control , Proteomics , RNA, Messenger/metabolism , Risk Assessment
12.
Complement Ther Med ; 16(6): 336-42, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19028334

ABSTRACT

OBJECTIVE: This study uses a nationwide population-based dataset to explore factors and patterns associated with traditional Chinese medicine (TCM) usage among schizophrenia patients. DESIGN: A retrospective population-based study. Administrative claims data obtained from the Taiwan National Health Insurance Research Database covering the periods 1996-2004 was used to examine patients hospitalized with schizophrenia between 1996 and 2001 (n=34,100) to determine whether they had visited TCM practitioners in 2004 for treatment of schizophrenia. SETTING: Taiwan. MAIN OUTCOME MEASURES: Independent variables included patient's age, gender, comorbid medical disorders, number of visits to clinics, number of hospitalizations, income and the geographical location and urbanization level of patients' residences. Multivariate logistic regressions were performed to determine the association between these factors and visits to TCM practitioners for the treatment of schizophrenia. RESULTS: 3144 of the patients (9.2%) had visited TCM practitioners during 2004. After adjusting for other factors, the odds of such visits by males were found to be 0.825 times those for females, with the odds decreasing with patient's age and urbanization level. The odds of visits to TCM practitioners for patients hospitalized more than once were 3.557 times as high as those for other patients, while those for patients with >or=50 prior visits to other conventional clinics were 54.9 times those with

Subject(s)
Medicine, Chinese Traditional/statistics & numerical data , Schizophrenia/therapy , Adolescent , Adult , Age Factors , China , Female , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Sex Factors , Young Adult
13.
Glia ; 56(13): 1390-400, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18618653

ABSTRACT

Reactive gliosis caused by post-traumatic injury often results in marked expression of chondroitin sulfate proteoglycan (CSPG), which inhibits neurite outgrowth and regeneration. Methylprednisolone (MP), a synthetic glucocorticoid, has been shown to have neuroprotective and anti-inflammatory effects for the treatment of acute spinal cord injury (SCI). However, the effect of MP on CSPG expression in reactive glial cells remains unclear. In our study, we induced astrocyte reactivation using alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and cyclothiazide to mimic the excitotoxic stimuli of SCI. The expression of glial fibrillary acidic protein (GFAP), a marker of astrocyte reactivation, and CSPG neurocan and phosphacan were significantly elevated by AMPA treatment. The conditioned media from AMPA-treated astrocytes strongly inhibited neurite outgrowth of rat dorsal root ganglion neurons, and this effect was reversed by pretreatment with MP. Furthermore, MP downregulated GFAP and CSPG expression in adult rats with SCI. Additionally, both the glucocorticoid receptor (GR) antagonist RU486 and GR siRNA reversed the inhibitory effects of MP on GFAP and neurocan expression. Taken together, these results suggest that MP may improve neuronal repair and promote neurite outgrowth after excitotoxic insult via GR-mediated downregulation of astrocyte reactivation and inhibition of CSPG expression.


Subject(s)
Astrocytes/drug effects , Astrocytes/physiology , Chondroitin Sulfate Proteoglycans/antagonists & inhibitors , Chondroitin Sulfate Proteoglycans/biosynthesis , Glial Fibrillary Acidic Protein/antagonists & inhibitors , Glial Fibrillary Acidic Protein/biosynthesis , Methylprednisolone/pharmacology , Animals , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Chondroitin Sulfate Proteoglycans/genetics , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Glial Fibrillary Acidic Protein/genetics , Rats , Rats, Sprague-Dawley
14.
Reprod Med Biol ; 4(2): 93-99, 2005 Jun.
Article in English | MEDLINE | ID: mdl-29699214

ABSTRACT

The physiological changes in endometriosis involving multiple steps of matrix remodeling include abnormal tissue growth, invasion, and adhesion formation. Endometriosis-associated abnormal matrix remodeling is affected by several molecular factors including proteolytic enzymes and their inhibitors, which mediate tissue turnover throughout the reproductive tract to maintain the integrity of the endometrium, and ovarian steroids, which normally regulate reconstruction and breakdown of endometrium in the menstrual cycle. In addition, various growth factors, such as platelet-derived growth factor, transform growth factor ß, and epidermal growth factor, direct modulation of growth, activation, and chemotaxis which may facilitate endometrial cell adhesion onto the peritoneal mesothelium during the development of endometriosis. Furthermore, cell adhesion molecules are believed to be critically involved in most cellular-level processes including cellular differentiation, motility, and attachment with the extracellular matrix. The present review focuses on the abnormal matrix remodeling process and its possible regulatory mechanism in association with endometriosis development. As a greater understanding of the cause of endometriosis is achieved, better treatment of the disease and its prevention become possible. (Reprod Med Biol 2005; 4: 93-99).

15.
Best Pract Res Clin Obstet Gynaecol ; 18(2): 305-18, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15157644

ABSTRACT

Endometriosis is a benign but aggressive disease. It occurs when shed endometrium from the female reproductive tract grows at a site outside the uterus. The physiological changes in endometriosis-abnormal tissue growth, invasion, and adhesion phenomena-are similar to those seen in tumorous tissues. Although the etiology of endometriosis is not well understood, the disease is widely accepted to result from the ectopic implantation of refluxed menstrual tissues. In addition, immunologic changes, genetic factors, and environmental factors might also affect a woman's susceptibility to develop endometriosis. Thus far, laparoscopic examination is required to confirm the presence of endometriosis; there is no reliable marker for its diagnosis. Many studies are therefore focusing on identifying markers for the diagnosis and follow-up of endometriosis. This chapter provides a systematic review of these studies, including recent findings from our group on the identification of molecules, in serum and/or endometrium, which are associated with the development of endometriosis at different stages. From this research, we hope to be able to suggest how to approach the potential markers. The identification of highly sensitive and specific markers of endometriosis should facilitate the development of accurate and non-invasive techniques for diagnosis and prognosis.


Subject(s)
Biomarkers/analysis , Endometriosis/diagnosis , Endometrium/chemistry , Autoantibodies/blood , Biomarkers/blood , Cell Adhesion Molecules/analysis , Cytokines/blood , Endometriosis/genetics , Female , Genetic Predisposition to Disease , Growth Substances/blood , Humans , Matrix Metalloproteinases/blood , Oligonucleotide Array Sequence Analysis/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...